All In Biotech

Drug Trial Radar · NCT05810116

Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain

Effect of Palmitoylethanolamide (PEA) Compared to a Placebo on Acute Menstrual Pain in an Adult Population - a Double-blind, Crossover, Randomised Controlled Trial.

Last checked: Nov 20, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

May 19, 2023

Primary completion

Dec 20, 2023

Study completion Dec 20, 2023

Sponsor

Lead sponsor
RDC Clinical Pty LtdIndustry
Sponsor type
Industry
First posted
Apr 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Palmitoylethanolamide (PEA) compared to placebo on menstrual pain in otherwise healthy participants 18 years and over.

Conditions

  • Menstrual Pain

Interventions

  • Levagen+Drug

    Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)

  • Microcrystalline celluloseDrug

    Daily dose of 1-2 capsules (1 capsule containing 350mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in acute menstrual pain severity, analgesic effect via Numeric Rating Scale (NRS)Time frame: 4 menstrual pain events over a maximum of 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • RDC Clinical Pty Ltd

    New Farm, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.